Patents by Inventor Taosheng Chen

Taosheng Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12053446
    Abstract: Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: August 6, 2024
    Assignees: Ting Therapeutics LLC, St Jude Children's Research Hospital
    Inventors: Tal Teitz, Jian Zuo, Taosheng Chen
  • Publication number: 20240246941
    Abstract: Testis-restricted melanoma antigen (MAGE) proteins are frequently hijacked in cancer and play a critical role in tumorigenesis. These proteins assemble with E3 ubiquitin ligases and function as substrate adaptors that direct the ubiquitination of novel targets, including key tumor suppressors. However, the development of MAGE-directed therapeutics heretofore has been extremely limited. In one aspect, the disclosure relates to compounds and peptides useful as inhibitors of MAGE-All: substrate interaction, methods of making same, pharmaceutical compositions comprising same, and methods of treating a disorder associated with a MAGE-All dysfunction. e.g., a cancer, using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Application
    Filed: July 15, 2021
    Publication date: July 25, 2024
    Inventors: Ryan POTTS, Taosheng CHEN, Zoran RANKOVIC, Jaeki MIN, Wenwei LIN, Seung Wook YANG, Anand MAYASUNDARI
  • Publication number: 20240139315
    Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: Jian ZUO, Fei ZHENG, Tetsuji YAMASHITA, Zoe KELLARD, Tal TEITZ, Jaeki MIN, Taosheng CHEN
  • Patent number: 11883491
    Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: January 30, 2024
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
  • Publication number: 20240002458
    Abstract: The present disclosure relates to compositions and methods for use in modulating von Hippel-Lindau protein (pVHL) and in identifying pVHL ligands, which can be useful in, for example, treating anti-chronic anemia and anti-chronic ischemia, and also as proteolysis targeting chimeras (PROTACS) to degrade proteins for various therapeutic applications. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 8, 2021
    Publication date: January 4, 2024
    Inventors: Taosheng Chen, Wenwei Lin, Yongtao Li
  • Patent number: 11446308
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: September 20, 2022
    Inventors: Jian Zuo, Tai Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
  • Publication number: 20220091120
    Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).
    Type: Application
    Filed: December 3, 2021
    Publication date: March 24, 2022
    Inventors: J. Paul TAYLOR, Peiguo YANG, Wenwei LIN, Taosheng CHEN
  • Patent number: 11237168
    Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: February 1, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: J. Paul Taylor, Peiguo Yang, Wenwei Lin, Taosheng Chen
  • Patent number: 10947203
    Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles having a structure represented by a formula: which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: March 16, 2021
    Assignee: ST. JUDE CHILDREN'S RSEARCH HOSPITAL
    Inventors: Taosheng Chen, Wenwei Lin, Yueming Wang
  • Publication number: 20200408759
    Abstract: A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).
    Type: Application
    Filed: June 26, 2019
    Publication date: December 31, 2020
    Applicant: St. Jude Children's Research Hospital
    Inventors: J. Paul TAYLOR, Peiguo YANG, Wenwei LIN, Taosheng CHEN
  • Publication number: 20200179397
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 11, 2020
    Inventors: Jian Zuo, Tal Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
  • Publication number: 20200093923
    Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
    Type: Application
    Filed: April 30, 2018
    Publication date: March 26, 2020
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALEINDHOVEN
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
  • Publication number: 20200071281
    Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles, which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 8, 2019
    Publication date: March 5, 2020
    Inventors: Taosheng Chen, Wenwei Lin, Yueming Wang
  • Patent number: 10550091
    Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles, which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: February 4, 2020
    Assignee: St. Jude Children's Research Hospital
    Inventors: Taosheng Chen, Wenwei Lin, Yueming Wang
  • Publication number: 20190077770
    Abstract: In an aspect, the invention relates to 1,4,5-substituted 1,2,3-triazole and 1,2,4,5-substituted imidazoles, which are modulators the pregnane X receptor (“PXR”); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of modulating an adverse drug reaction in a mammal using the compounds and pharmaceutical compositions; methods of treatment of a disorder of uncontrolled cellular proliferation, such as a cancer, using the compounds and pharmaceutical compositions; methods of modulating pregnane X receptor activity in a mammal using the compounds and pharmaceutical compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 10, 2017
    Publication date: March 14, 2019
    Inventors: Taosheng CHEN, Wenwei Lin, Yueming Wang
  • Publication number: 20180161340
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 20, 2016
    Publication date: June 14, 2018
    Inventors: Jian Zuo, Tai Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
  • Patent number: 9908890
    Abstract: The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: March 6, 2018
    Assignee: St. Jude Children's Research Hospital
    Inventors: Taosheng Chen, Milu Cherian, Wenwei Lin
  • Publication number: 20170226115
    Abstract: The compounds of the invention are antagonists of CAR, with specificity for CAR over other proteins including PXR. The disclosed compounds are useful in treating or controlling cell proliferative disorders, in particular oncological disorders, such as cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: October 16, 2015
    Publication date: August 10, 2017
    Inventors: Taosheng CHEN, Milu Cherian, Wenwei Lin
  • Publication number: 20170189477
    Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: December 29, 2016
    Publication date: July 6, 2017
    Inventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters
  • Patent number: 9572815
    Abstract: In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27Kip1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising ?-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: February 21, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Taosheng Chen, Brandon Walters, Bryan Kuo, Bradley Walters